Clinical Trial Update: A Study Investigating the Immunologic Effects and Safety of 60-day Treatment of the ALK HDM Tablets in Adult Subjects With HDM-Induced Allergic Rhinitis and/or Atopic Asthma [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the immunologic effects and safety of a 60-day course of ALK HDM Sublingual Immunotherapy Tablets in adults with house dust mite-induce…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis
• Asthma

Drugs mentioned

• ALK HDM Tablet

Snippet

Sponsor: Abbott | Conditions: Allergy, Asthma | Phase 3 | Status: COMPLETED | Results posted: 2017-12-18